How zombie startups are made
July 1, 2026
How zombie startups are made
A zombie startup is a company that is too alive to die and too stuck to matter. It has revenue — often real revenue. It has customers, a team, a product people use. What it doesn't have is a path to the outcome its capital was priced for. It can't raise the next round, can't grow into its last valuation, and can't fail cleanly either, because it's still paying salaries. So it persists — neither alive in the sense its investors meant, nor dead in the sense that would free anyone to start again.
The startling thing about zombies isn't how they end up. It's how they begin: almost always as good companies. Nobody sets out to build one, and very few zombies were bad ideas badly executed. They're something more uncomfortable — the predictable output of a specific sequence, run by rational people responding to the incentives in front of them.
That sequence deserves to be understood, because it's still running.
The sequence
Step one: the company finds real demand. This is worth stressing — the zombie story starts with success. Product-market fit, genuinely. Paying customers, genuinely. The first gate, passed.
Step two: capital arrives, priced on the curve. The round is raised on growth and the promise of more of it. The valuation encodes an outcome — a big one — and from this moment the company is contractually sprinting toward it, whether or not anyone has checked that the route exists.
Step three: the spend chases the curve. Rationally. The metric that raised the last round is the metric that will raise the next one, so the money goes to paid acquisition, sales headcount, more surface area — the visible machinery of growth. Everything that would make the growth harder to take away is postponed, because it doesn't move the curve this quarter and nobody is asking about it yet.
Step four: the environment turns, and the growth is re-tested. A funded competitor arrives, or the channel saturates, or the market reprices — as it has, brutally, since 2022 (I've written about what that repricing changed here). Suddenly the question isn't "how fast are you growing?" but "what would we be buying if the growth slowed?" For a lot of companies, the honest answer is: last quarter's growth, re-purchased every quarter at rising cost.
Step five: the trap closes. The company is too expensive to fund toward its priced outcome, too healthy to shut down, and too tied to its last valuation to reset cheaply. Investors triage their attention toward the winners. The board meetings get shorter. The company keeps operating — sometimes for years. That's the zombie: not a death, a suspension.
Why nobody stops the sequence
Every actor in the sequence behaves rationally. The founder sprints because the last round's price demands it. The investors encourage the sprint because their model needs the outlier outcome, and a portfolio logic tolerates deaths better than modest exits. The team builds what the roadmap says. At no point does anyone make an obvious mistake — which is precisely why the pattern repeats. The sequence isn't a failure of intelligence. It's a system doing what it's priced to do, with one question systematically unasked: is the thing being built getting harder to take away, or just bigger?
That question has no owner. Growth has a dashboard, a team, and a board slide. Durability has a vague adjective and a hope. When one side of a trade-off is measured weekly and the other is measured never, the outcome isn't in doubt.
The honest way out
If you suspect you're inside this sequence, there are genuinely different paths, and the worst move is refusing to choose one.
Some companies should keep sprinting — because underneath the growth, something real is accumulating: customers who would lose a lot by leaving, a position a competitor can't cheaply replicate. For these companies the sprint is right; it just needs to be pointed deliberately at deepening that position rather than assuming it deepens itself.
Some companies should redirect the spend — because the durable position is available but the money has been buying the curve instead. This is the most common case and the most fixable, if it's caught while there's runway. The redirect feels like slowing down. It's usually the only version of speeding up that survives contact with the next diligence.
And some companies should reset the goal — because the big outcome the last valuation priced isn't reachable from here, and every quarter of pretending otherwise burns the money that could have built a genuinely good business at the scale the market actually supports. This is the option nobody's incentives are arranged to say out loud. Founders don't want to hear it, boards don't want to book it, and advisors don't get paid for it. Which is exactly why the companies that choose it early are so rare — and, several years later, so conspicuously better off than the zombies that didn't.
The tragedy of the zombie isn't the death that never comes. It's the good smaller company that was available the whole time, foreclosed by the pursuit of an outcome the structure was never going to carry.
The question to ask before the market asks it
All three paths start from the same act: an honest read of what's actually underneath the growth — what holds your customers, what a funded competitor could and couldn't take, and whether the destination your capital is priced for is reachable from where you stand. Most companies have never had that read done. The metrics don't provide it; they're the surface, and the zombie sequence runs entirely on companies mistaking the surface for the structure.
Getting that read early — before a raise, not during one — is the work I do with post-product-market-fit founders: what it involves →. And how investors make this judgement in the wild is the subject of The Defensibility Study, a formal research programme currently in fieldwork: take part →.
The zombie sequence is predictable. Which means it's interruptible — but only from the inside, and only early.
Iain Acton — defensibility researcher and advisor · author of The Defensibility Study and the forthcoming book The Second Gate